Description: Asensus Surgical, Inc. engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. It digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through a new category of care called Digital Laparoscopy. The company's digital interface enables the use of capabilities, such as augmented intelligence, connectivity, and robotics in laparoscopy, as well as allows to address the current clinical, cognitive, and economic shortcomings in surgery. The company's products include Senhance Surgical System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and internationally. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Morrisville, North Carolina.
Home Page: www.asensus.com
ASXC Technical Analysis
1 TW Alexander Drive
Durham,
NC
27703
United States
Phone:
919 765 8400
Officers
| Name | Title |
|---|---|
| Mr. Anthony Fernando | Pres, CEO & Director |
| Mr. Shameze Rampertab B.Sc. MBA, CA, CPA | Exec. VP & CFO |
| Mr. Joshua B. Weingard | Chief Legal Officer & Sec. |
| Mr. Paul Ziegler Jr., J.D. | VP of Sales |
| Ms. Amanda Owens | Global Head of People |
| Dr. Stephanie M. Fitts Ph.D. | VP of Clinical, Quality and Regulatory Affairs |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8323 |
| Price-to-Sales TTM: | 12.4108 |
| IPO Date: | 1992-11-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 153 |